REBOOT試験からのポストホック分析
Xavier Rossello1,2,3, Pedro L Sánchez3,4, Ruth Owen1,5
1Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
まとめ
心筋梗塞 (MI) の後のベータブロッカーの離脱は,保存されたエジェクション分数 (LVEF> 40%) の患者に安全です. この集団では,ベータブロッカーの投与を控えたり,中止しても,短期的または再発性血栓不全が増加しなかった.
科学分野:
- 心臓病科
- 臨床試験
- 薬理学について
背景:
- 現在のガイドラインでは,左心室排出分数 (LVEF) にかかわらず,心筋梗塞 (MI) の後のベータブロッカーを推奨しています.
- 最近の試験では,LVEFが保存された患者 (LVEF> 40%) でこの慣行が疑問視されている.
- このサブグループにおけるベータブロッカーの離脱の安全性については不確実性がある.
研究 の 目的:
- LVEF > 40% の心筋梗塞患者の退院時にベータブロッカーの短期的な安全性を評価する.
- 血液不全事件の複合エンドポイントに対するベータブロッカー療法の影響を評価する.
主な方法:
- REBOOT試験のデータを分析した.
- MIとLVEF > 40% の患者でベータブロッカーを投与するか,出院時に投与しないかをランダムに決定した.
- 短期 (3ヶ月) と再発性血栓不全の発生率が評価され,追跡期間の中央値は3. 7年であった.
主要な成果:
- ベータブロッカーの服用を控えたり,服用を中止したりすると,短期的な発血リスクが増加することはなかった (HR 1.13,95%CI: 0. 74-1.72).
- グループ間では,再発性不全症の有意な差異は認められなかった (HR 0. 98, 95% CI: 0. 82-1. 16).
- 以前治療を受けた患者のベータブロッカーの離脱は,血栓不全のリスクを高めなかった (HR 0. 93, 95% CI: 0. 64 - 1. 34).
結論:
- 退院時にベータブローカーの投与を止めることは,LVEF> 40% の心筋梗塞患者にとって安全です.
- この戦略は,これらの患者の管理における現在の臨床慣行を支えている.
- 短期的または再発性血栓不全のリスク増加は認められなかった.
さらに関連する動画
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
24.4K
06:32Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
Published on: June 28, 2019
8.1K
関連する概念動画
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
970
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
970
01:28Antihypertensive Drugs: Types of β-Blockers
863
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
863
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
845
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
845
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
597
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505